Wigge & Partners’ Banking & Finance team advised the European Investment Bank (EIB) in connection with a loan facility to Oncopeptides AB (publ), to be used to further support the company´s clinical development of melflufen. The facility entitles EIB to a predetermined number of warrants in Oncopeptides.
Wigge & Partners’ team consisted of Lisa Antman as responsible partner together with associates Andreas Malmberg and Fredrik Arvebratt
Read more in Dagens Industri https://www.di.se/live/oncopeptides-tecknar-laneavtal-pa-414-mkr-ska-stodja-expansionen/
